Comparative Pharmacology
Head-to-head clinical analysis: HAILEY FE 1 5 30 versus VOLNEA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HAILEY FE 1 5 30 versus VOLNEA.
HAILEY FE 1.5/30 vs VOLNEA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination estrogen-progestin contraceptive that suppresses gonadotropin release (FSH and LH) from the pituitary, inhibiting ovulation. Additionally, increases viscosity of cervical mucus and alters endometrial receptivity.
Volnea is a combination of dienogest and ethinylestradiol. Dienogest is a progestin with antiandrogenic activity, and ethinylestradiol is an estrogen. The contraceptive effect is achieved through suppression of gonadotropins (FSH and LH), inhibition of ovulation, and changes in cervical mucus and endometrium.
One tablet orally once daily for 21 consecutive days, followed by 7 days of placebo tablets.
One tablet (0.02 mg ethinylestradiol + 3 mg drospirenone) orally once daily for 21 consecutive days, followed by a 7-day hormone-free interval.
None Documented
None Documented
Ethinyl estradiol: terminal half-life ~17-24 hours; norethindrone: terminal half-life ~5-14 hours (mean 11 hours). The clinical significance is that steady-state is reached within 5-7 days.
Terminal half-life: 12 hours (range 10-14 h). Supports twice-daily dosing in patients with normal renal function.
Ethinyl estradiol is primarily excreted renally (40-45%) and via bile/feces (45-55%). Norethindrone is excreted 50-60% renally and 30-40% fecally.
Renal: 70% unchanged; fecal: 30% (biliary elimination)
Category C
Category C
Oral Contraceptive
Oral Contraceptive